Firocoxib

Firocoxib (ML 1785713) is a potent, selective and orally active COX-2 inhibitor with an IC50 of 0.13 μM. Firocoxib shows 58-fold more selective for COX-2 than COX-1 (IC50 of 7.5 μM) . Firocoxib has anti-inflammatory effects[1].

Product Specifications

CAS Number

[189954-96-9]

Product Name Alternative

ML 1785713

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

COX

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Firocoxib.html

Concentration

10mM

Purity

99.54

Solubility

DMSO : ≥ 52 mg/mL

Smiles

O=C1OC(C)(C)C(C2=CC=C(S(=O)(C)=O)C=C2)=C1OCC3CC3

Molecular Formula

C17H20O5S

Molecular Weight

336.40

Precautions

H302, H315, H319, H335

References & Citations

[1]Steagall PV, et al. Evaluation of the adverse effects of oral firocoxib in healthy dogs. J Vet Pharmacol Ther. 2007 Jun;30 (3) :218-23.|[2]Stock ML, et al. Pharmacokinetics of firocoxib in preweaned calves after oral and intravenous administration. J Vet Pharmacol Ther. 2014 Oct;37 (5) :457-63.|[3]Albanese F, et al. Clinical outcome and cyclo-oxygenase-2 expression in five dogs with solar dermatitis/actinic keratosis treated with firocoxib. Vet Dermatol. 2013 Dec;24 (6) :606-12, e147.|[4][1].McCann ME, et al. In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in cats with lipopolysaccharide-induced pyrexia. Am J Vet Res. 2005 Jul;66 (7) :1278-84.